Thanks very much.
First off, on behalf of the University of Saskatchewan, welcome to our beautiful city and province, particularly on this wonderful prairie summer day.
Thank you for the opportunity to appear before you. Here with me today is my colleague Doug Gill, who is the managing director of our industry liaison office.
My objective today is to first give you a brief overview of our innovation and science and technology cluster at the University of Saskatchewan. Then I'd like to share some thoughts, as we started to talk about this morning, on what is for us our single largest issue with regard to science and technology, and that is the funding of operating costs for major scientific facilities.
At the University of Saskatchewan we're proud to be in our 101st year. To give you a sense of the scale of the institution, we have over 20,000 students, 7,000 staff, and 13 different colleges. We've created an innovation cluster that is a global leader that we believe will continue to benefit Saskatoon, Saskatchewan, and Canada.
One of the unique elements of our cluster is that we're one of the only universities in the country that has that unique combination of human, animal, and plant sciences with our colleges of medicine, nursing, pharmacy, nutrition, veterinary medicine, and agriculture and bio-resources. Adding to that are, of course, VIDO and our new International Vaccine Centre, together with the biomedical imaging beam lime at the CLS, creating a very unique cluster and capability in the life sciences.
It's those types of combinations that have helped us to be a leader in innovation. Our overall research revenue at the university is now more than $140 million, more than double what it was 10 years ago. So we are in a growth trajectory and seek to continue to build on our success in research.
One of the early successes that paved the way for this level of achievement, and you've heard about it already from Ken Loeppky, is Innovation Place. It's one of the most successful university-related research parks in North America. Ken shared with you some of the stats. With 150 clients, 2,700 employees, it's a very significant entity and a great success story. Actually, as you travel around the world you realize it's one of the early success stories in science and technology parks, having been there in the early eighties. I spent some time in the U.K., and I can say that a lot of countries are probably 10 years behind where we were in Saskatchewan in establishing these types of facilities.
Of course, the other aspect to our cluster, our major science facilities, as we spoke about this morning, is that across the country there are approximately 10 pieces of major science infrastructure, that is, greater than $100 million. Two of them are here in Saskatoon. One is the Canadian Light Source, and the second is the International Vaccine Centre.
As you heard, the CLS is an international facility. It has researchers and funding partners from across Canada and around the world, capital funding from four provinces, active researchers from eight provinces, and, as I understand, we're working on P.E.I. and Newfoundland to get them on board as well. CLS is a very ambitious industrial science program, targeting 25% of its beam time to industrial partners and cost recovery, and we're on track to working towards those goals.
But as I mentioned, the CLS isn't the only major science endeavour. There's also the International Vaccine Centre, the $140 million facility on track to be constructed in 2010. When it is completed it will be the largest containment level 3 research facility in western Canada. What that means is you'll have the capacity to investigate--I think you heard about it already from our colleagues from VIDO--and conduct research on those level 3 diseases that are at the boundaries of animal-human health, some of the hottest topics in public health these days, such as avian influenza, West Nile virus, and SARS.
As you've heard from VIDO, the predecessor organization of InterVac, this facility will have an impact well beyond Saskatchewan borders. For example, we know from VIDO that their calf scours livestock vaccine saved an estimated $5 billion in economic losses per year across North America. So it's a very significant economic impact that you can have directly or indirectly through these types of facilities.
That gives you a bit of history of where we've come from as an institution and where we are today in terms of contributing to Canada's research excellence. Looking forward, of course, we see a range of opportunities and barriers to our continued success in research, but the single biggest issue for us is funding the operating costs of major scientific facilities, such as CLS and InterVac.
The Government of Canada's vision for science and technology is really to build a sustainable national competitive advantage in science and technology. I think from your tour this morning you've had a sense of how major facilities like CLS and InterVac will bring that vision to life, creating those critical masses that can bring together people and investment from across the country and around the world.
As you know, we don't have a framework or single agency to deal with operating costs for major scientific facilities. The CLS currently receives funding from a variety of provincial and federal partners, including NSERC, CIHR, NRC, and Western Economic Diversification Canada. And while we're grateful for this, we also recognize that other nations, such as the United States, have a single agency.
So our key recommendation to you, to give you a bit more detail, is that the Government of Canada provide a program of sustainable funding for major scientific facilities like CLS and InterVac.
The program, I think, should have a number of key features, which we can talk a little more about. It should, for example, provide funding over a five-year timeframe, to give some stability. The program should likely include the requirement of some modest provincial contributions. We believe science and technology is primarily a federal responsibility, but requiring some provincial matching would ensure that major labs continue to serve the needs of their local communities. As well, obviously the industrial targets are a very important component of this.
I want to be clear that we're happy working with our current funding partners, but we do see benefits to the public of establishing a single agency such as this. It would provide more focused and effective oversight of the facilities, a little more monitoring of their strategic goals, a potentially stronger link between government strategy and their direction, and perhaps enhance capacity to create industrial partnerships.
I've covered a lot of ground. I know we'll talk more about this in questions, but to summarize, I hope I've left you with a clearer picture of what our cluster is here and some of the major issues and how we might work together to resolve this issue of operating costs for major facilities.